The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Testosterone Replacement Therapy in Patients with Prostate Cancer After Radical Prostatectomy
Open accessAbstract
PURPOSE: Testosterone replacement therapy in men with prostate cancer is controversial, with concern that testosterone can stimulate cancer growth. We evaluated the safety and efficacy of testosterone in hypogonadal men with prostate cancer treated with radical prostatectomy. MATERIALS AND METHODS: We performed a review of 103 hypogonadal men with prostate cancer treated with testosterone after prostatectomy (treatment group) and 49 nonhypogonadal men with cancer treated with prostatectomy (reference group). There were 77 men with low/intermediate (nonhigh) risk cancer and 26 with high risk cancer included in the analysis. All men were treated with transdermal testosterone, and serum hormone, hemoglobin, hematocrit and prostate specific antigen were evaluated for more than 36 months. RESULTS: Median (IQR) patient age in the treatment group was 61.0 years (55.0-67.0), and initial laboratory results included testosterone 261.0 ng/dl (213.0-302.0), prostate specific antigen 0.004 ng/ml (0.002-0.007), hemoglobin 14.7 gm/dl (13.3-15.5) and hematocrit 45.2% (40.4-46.1). Median followup was 27.5 months, at which time a significant increase in testosterone was observed in the treatment group. A significant increase in prostate specific antigen was observed in the high risk and nonhigh risk treatment groups with no increase in the reference group. Overall 4 and 8 cases of cancer recurrence were observed in treatment and reference groups, respectively. CONCLUSIONS: Thus, testosterone therapy is effective and, while followed by an increase in prostate specific antigen, does not appear to increase cancer recurrence rates, even in men with high risk prostate cancer. However, given the retrospective nature of this and prior studies, testosterone therapy in men with history of prostate cancer should be performed with a vigorous surveillance protocol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Limited data have demonstrated no significant increases in prostate cancer recurrence in men treated with testosterone compared to controls”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [36]
The cited source says what the claim attributes to it.
In the citing paper
“although an increase in PSA among men in high-risk groups receiving testosterone has been shown”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [36]
In the citing paper
“As such, insufficiently powered studies which conclude safety of T supplementation in men with prostate cancer are at risk of committing type-II errors and are not statistically supportable.143, 144”
From Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials (2016) · cites this paper as [144]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Investigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Cookson, M. S., Aus, G., Burnett, A. L. “., Canby‐Hagino, E., D'Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., Goldenberg, S. L., Hernández, J., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.10.097 · Cited by 848
Calof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728
Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden, E. L., & Morgentaler, A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022251 · Cited by 705
Huggins, C., & Hodges, C. (2002) · Journal of Urology · doi:10.1016/s0022-5347(02)80307-x · Cited by 637
Morgentaler, A., & Traish, A. M. (2008) · European Urology · doi:10.1016/j.eururo.2008.09.024 · Cited by 469
Wang, C., Nieschlag, E., Swerdloff, R. S., Behre, H. M., Hellstrom, W. J. G., Gooren, L. J., Kaufman, J., Legros, J. J., Lunenfeld, B., Morales, Á., et al. (2008) · Journal of Andrology · doi:10.2164/jandrol.108.006486 · Cited by 443
Marks, L. S., Mazer, N. A., Mostaghel, E., Hess, D. L., Dorey, F. J., Epstein, J. I., Veltri, R. W., Makarov, D. V., Partin, A. W., Bostwick, D. G., et al. (2006) · JAMA · doi:10.1001/jama.296.19.2351 · Cited by 400
Cited by
Sorted by citations
Evaluation and Management of Testosterone Deficiency: AUA Guideline
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2018.03.115 · Cited by 766
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men
Lunenfeld, B., Mskhalaya, G. J., Zitzmann, M., Arver, S., Kalinchenko, S. Y., Tishova, Y. A., & Morgentaler, A. (2015) · The Aging Male · doi:10.3109/13685538.2015.1004049 · Cited by 318
A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical Implications
Khera, M., Crawford, D., Morales, Á., Salonia, A., & Morgentaler, A. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.015 · Cited by 166
Self-citationDean, J. D., McMahon, C. G., Guay, A. T., Morgentaler, A., Althof, S. E., Becher, E. F., Bivalacqua, T. J., Burnett, A. L. “., Buvat, J., Meliegy, A. E., et al. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12952 · Cited by 159
Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk
Michaud, J. E., Billups, K. L., & Partin, A. W. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215597633 · Cited by 143
Metadata
- Authors
- Pastuszak, A. W., Pearlman, A. M., Lai, W. S., Godoy, G., Sathyamoorthy, K., Liu, J. S., Miles, B. J., Lipshultz, L. I., & Khera, M.
- Affiliations
- Baylor College of Medicine (US)
- University of Pennsylvania (US)
- Northwestern University (US)
- Houston Methodist (US)
- ORCID
- Venue
- Journal of Urology
- Published
- 2013-08
- Volume
- 190
- Issue
- 2
- Pages
- 639-644
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- PMC
- PMC4544840
- OpenAlex
- W2091445581
- Cited by
- 183
- References
- 33
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 9 · 2023: 9 · 2022: 18 · 2021: 6 · 2020: 15 · 2019: 15 · 2018: 11 · 2017: 10 · 2016: 13 · 2015: 27 · 2014: 26 · 2013: 6
- FWCI
- 18.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K23CA160664)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- testosterone replacement therapy, prostate cancer, radical prostatectomy, hypogonadism, transdermal testosterone, prostate-specific antigen, tumor recurrence, high-risk prostate cancer, low-risk prostate cancer, hemoglobin, hematocrit, hormone therapy safety
- MeSH terms
- Aged, Hematocrit, Hemoglobins, Humans, Hypogonadism, Male, Middle Aged, Prostatectomy, Prostatic Neoplasms, Retrospective Studies, Testosterone, Linear Models, Treatment Outcome, Prostate-Specific Antigen, Statistics, Nonparametric, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
